ASCO 2019: 5 Noteworthy Abstracts to be Presented at Annual Meeting

The American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois from May 31 to June 4, brings together oncology experts from around the world to share the latest updates in clinical cancer research.

This year, more than 32,000 oncology professionals will be in attendance. With many groundbreaking advancements and emerging therapies in the space, the meeting is expected to be packed with late-breaking abstracts, educational sessions, and more clinical updates on a variety of topics.

Specialty Pharmacy Times® is on site providing coverage of the conference in real time. Stay up to date with our daily conference newsletters each morning. You can sign up here for our e-newsletters to receive daily recaps straight to your inbox. Don’t forget to follow us on Facebook and Twitter as well for up-to-date coverage.

Here are some of the top highlighted abstracts to watch for in our coverage:

• Abstract 520: Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women’s Health Initiative randomized clinical trial.

This clinical trial of dietary modifications includes approximately 20 years of data and assesses the impact of a balanced, low-fat diet on the risk of death due to breast cancer among postmenopausal women.

• Abstract 7502: Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD-) in previously untreated patients (pts) with chronic lymphocytic (CLL) and comorbidities.

The multinational, open-label, phase 3 CLL15 trial compared fixed-duration targeted VenG treatment with chlorambucil plus obinutuzumab in previously-untreated patients with CLL and comorbidities. The endpoint analyses, with particular emphasis on MRD and PFS, will be presented at the meeting.

• Abstract 10011: Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.

Highlighting potential advancements in precision medicine for children is a study examining the frequency of targetable molecular alterations in pediatric cancers. The study includes patients enrolled in the phase 2 NCI-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (NCI-COG Pediatric MATCH) clinical trial.

• Abstract 500: Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.

The KRISTINE study, which will be presented at an oral abstract session during the conference, compared neoadjuvant chemotherapy plus dual HER2-blockade with T-DM1 plus P, a targeted regimen that omits chemotherapy. The investigators will present the final outcomes from the trial.

• Abstract LBA4505: EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.

This late-breaking abstract, which will be presented on June 3, involves a single-arm, phase 2 clinical trial exploring enfortumab vedotin monotherapy in patients with locally advanced or metastatic forms of urothelial cancer.